Oct 10 (Reuters) - 3d Signatures Inc DXD.V :
* On September 30, co completed clinical trial component or stage 3, of its Hodgkin's Lymphoma Test Validation Program
* Remain on track for expected commercial launch of Telo-HL(TM )as an LDT by end of Q1 2018